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26 Abstract
27 Background
28 High rates of antimicrobial resistance (AMR) in Neisseria gonorrhoeae hinder effective treatment, 
29 but molecular AMR diagnostics may help address the challenge. We aimed to appraise the literature 
30 for resistance-associated genotypic markers linked to fluoroquinolones and macrolides, to identify 
31 and review their use in diagnostics. 
32 Methods and Findings
33 Medline and EMBASE databases were searched and data pooled to evaluate associations between 
34 genotype and phenotypic resistance. Diagnostic accuracy estimates were limited by data availability, 
35 differences in mutations typed, and methods for reporting MIC.  1) S91 and D95 mutations in gyrA 
36 protein independently predicted ciprofloxacin resistance and used together gave 98.6% (95% 
37 confidence interval (CI) 98.0-99.0%) sensitivity and 91.4% (95% CI 88.6-93.7%) specificity; 2) the 
38 number of 23S rRNA gene alleles with C2611T or A2059G mutations was highly correlated with 
39 azithromycin resistance, with mutation in any allele giving sensitivity and specificity of 66.1% (95% CI 
40 62.1-70.0%) and 98.9% (95% CI 97.5-99.5%), respectively. Estimated negative (NPV) and positive 
41 predictive values for a 23S rRNA diagnostic were 98.6% (95% CI 96.8-99.4%) and 71.5% (95% CI 68.0-
42 74.8%) respectively; 3) mutations at amino acid positions G45 and H105 in MtrR protein 
43 independently predicted azithromycin resistance, however, when combined with 23S rRNA 
44 mutations, improved NPVs only marginally. 
45 Conclusions
46 Viable candidates for markers of resistance detection for incorporation into laboratory and point-of-
47 care diagnostics were demonstrated. Such tests may enhance antibiotic stewardship and treatment 
48 options. 
49
Page 2 of 26
www.publish.csiro.au/journals/sh
Sexual Health
For Review Only
3
50 Introduction
51 Patients attending sexual health clinics (SHCs) will often present with non-specific genital infections, 
52 associated with a number of common symptoms resulting from a diverse range of aetiologies. The 
53 number of potential causative agents can hinder effective management, which is highly dependent 
54 on an accurate and rapid diagnosis to inform prompt treatment. Difficulty in treatment is further 
55 compounded by increasing antimicrobial resistance (AMR) rates within sexually transmitted 
56 pathogens [1], threatening the efficacy of current treatment regimens, exemplified by recent UK 
57 reports of gonorrhoea resistant to azithromycin, part of the current first line treatment [2,3].
58 Current diagnostics commonly employ nucleic acid amplification tests (NAATs), favoured due to high 
59 sensitivity of detection and a quicker time to result than culture [4]. However, culture remains the 
60 only means of determining AMR profiles for gonococcal infection, but its use is in decline and results 
61 are often unavailable at time of diagnosis, meaning empirical management of genital syndromes is 
62 common [5]. Although empirical therapy helps to reduce time to treatment, onward transmission of 
63 infection and the possible loss to follow-up, it also risks induction and further spread of AMR. It also 
64 removes the opportunity for recycling older antibiotics that are likely to still be effective in many 
65 cases, but are no longer recommended for empirical use [6,7]. 
66 These challenges could in part be addressed by the development and deployment of NAAT 
67 technologies that identify both infection and AMR susceptibility in the laboratory and at the point of 
68 care (PoC), thereby enabling immediate administration of specific antibiotic therapy when patients 
69 are diagnosed (“precision medicine”). Calls for such novel diagnostics have been increasing in 
70 response to rising AMR rates [8,9] yet have been restricted in part by incomplete understanding of 
71 the relationship between bacterial genotype and treatment response.
72 Neisseria gonorrhoeae is a common sexually transmitted infection (STI) with high rates of AMR 
73 [10,11]. Fluoroquinolone and macrolide antibiotics, which represent both current and previously 
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74 recommended treatments for gonorrhoea [11], are effective in eradicating susceptible strains and 
75 are associated with specific genetic mechanisms of resistance. These typically centre on either 
76 alteration of the macrolide binding site through mutation or methylation of specific sites in the 23S 
77 rRNA for macrolide resistance[12], or mutations within the quinolone resistance-determining region 
78 (QRDR) of DNA gyrase (gyrA) or DNA topoisomerase IV (parC) for fluoroquinolone resistance[13, 14]. 
79 N. gonorrhoeae harbours up to four copies of the 23S rRNA allele, and the number of alleles carrying 
80 mutations can vary [15]. The activity of multi-drug efflux pumps can also influence minimum 
81 inhibitory concentration (MIC) to varying degrees [16]. 
82 As part of a body of work developing PoC tests for fluoroquinolone and macrolide resistance in M. 
83 genitalium and N. gonorrhoeae (www.preciseresearch.co.uk), this review aimed to appraise the 
84 literature on AMR genotype for N. gonorrhoeae in relation to fluoroquinolone and macrolide 
85 antibiotics and to test the strength of genotypic-phenotypic associations when pooling data from 
86 included publications. We also aimed to appraise the diagnostic accuracy of detecting AMR using 
87 genotypic markers identified in the review, in order to assess their suitability for inclusion on 
88 diagnostic platforms for AMR prediction.
89 Methods
90 Publication search strategy and screening criteria
91 Two separate searches were performed to reflect the aims: (1) macrolide resistance in N. 
92 gonorrhoeae and (2) fluoroquinolone resistance in N. gonorrhoeae. Preliminary review of the 
93 literature informed search term format, including the organism name, region associated with 
94 resistance (e.g. 23S rRNA for macrolides or gyrA and parC for fluoroquinolones) and a broader 
95 component comprising variations on “genotype” and the target antibiotic. This approach was used in 
96 an effort to ensure more general or emerging resistance mechanisms could still be detected (S1 
97 Text). Publication screening and data extraction were shared between two people and performed in 
98 September 2016 using OvidSP to search both EMBASE and Medline databases.
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99 Abstracts were screened to determine publication suitability for inclusion in the review (Table 1), 
100 with full text searched where necessary. Included publications had to target organism of interest and 
101 antibiotic of interest, and report resistance-associated genotype in relation to antibiotic of interest, 
102 with no date restriction applied. Exclusion criteria were: publications that were not available in 
103 English language or reviews and conference abstracts where results were available in full 
104 publication. Due to variations in data provision and quality, further exclusion criteria were applied to 
105 limit publications to those providing the level of detail required for data analysis of phenotypic-
106 genotypic relationships. Publications excluded at this stage were limited to the literature review only 
107 and used as a source of additional information for included papers, especially if two publications 
108 were linked. Exclusion criteria for data analysis were: mutation listed to gene level only; number of 
109 isolates/samples with each mutation not stated; reference strains and laboratory strains only; and 
110 repeat data sets. Some publications containing data constituting an exclusion criteria (e.g. reference 
111 strains), were extracted if this was clearly differentiated from the usable sample set. Publications 
112 included for data analysis (S2 Text) and relevant reviews underwent reference and citations 
113 checking. 
114 Data Extraction 
115 Optimal data capture from each eligible publication included: genotyping methodology; coverage 
116 and capacity to detect all mutations (e.g. targeted single nucleotide polymorphisms (SNPs) or 
117 sequencing of relevant gene regions); whether samples were randomly selected or stratified by 
118 phenotypic characteristics; susceptibility phenotype and/or treatment outcome (including test of 
119 cure methodology and timing); position of mutation; new base and/or amino acid following 
120 mutation; treatment regimen and dose; and whether the study had pre- and post-treatment data 
121 available. All samples/isolates were treated as separate cases except repeat data sets and those 
122 identified as pre- and post- treatment samples (S3 and S4 Data). 
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123 If the minimum inhibitory concentration (MIC) to a number of fluoroquinolones or macrolides was 
124 reported, analysis centred on ciprofloxacin and azithromycin, respectively, as these are either in use 
125 or have been recommended for treatment previously. Numbering of nucleotide bases or amino acid 
126 residue positions are in Escherichia coli numbering for macrolide resistance and N. gonorrhoeae 
127 numbering for fluoroquinolone resistance. 
128 Data Analysis
129 Variation in the level of detail provided in each publication made comparison of the entire database 
130 unreliable so set criteria were defined for each analysis (Table 2), with studies or samples/isolates 
131 only included if these were met. 
132 In order to standardise the thresholds for resistance and susceptibility for isolates of N. 
133 gonorrhoeae, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines 
134 [17] were referenced to assign resistance phenotypes based on MICs described in each publication. 
135 EUCAST guidelines define ciprofloxacin resistance in N. gonorrhoeae as a MIC >0.06 mg/L, which was 
136 used for this analysis. However, many studies used ≤0.06 mg/L as a susceptibility threshold, 
137 therefore not differentiating between intermediate (0.06 mg/L) and sensitive (≤0.03 mg/L) isolates, 
138 as defined by EUCAST. Therefore, all isolates with an MIC of ≤0.06 mg/L were assigned as non-
139 resistant. A similar approach was taken for azithromycin resistance in N. gonorrhoeae, with an MIC 
140 of >0.5 mg/L assigned as resistant and ≤0.5 mg/L as non-resistant with resistant isolates further 
141 categorised as low-level resistant (>0.5 mg/L and <2 mg/L), moderate-level resistance (≥2 mg/L and 
142 <256 mg/L) and high-level resistant (≥256 mg/L).
143 Statistical Methods
144 All statistical analysis was performed in Stata/IC 14 (Stata Corp, Texas). χ2 and univariate logistic 
145 regression analyses were performed for macrolide and fluoroquinolone resistance in N. gonorrhoeae 
146 to determine if presence of a mutation was significantly higher in isolates/samples with resistant MICs 
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147 or treatment failure. This was followed by multivariate logistic regression analyses using univariate 
148 variables at p<0.05 in a forward stepwise approach to determine the strength of each genotype as 
149 independent markers of resistance. The correlation between the numbers of mutated 23S rRNA alleles 
150 for N. gonorrhoeae and level of macrolide resistance was analysed using Spearman’s rank-order 
151 correlation coefficient. Sensitivity and specificity of resistance detection for the genotypic markers of 
152 AMR determined in this review were calculated using the following definitions: presence of AMR 
153 marker in resistant isolates/samples as true positive, in non-resistant isolates/samples as false 
154 positive, their absence (wild-type) in non-resistant isolates/samples as true negative and in resistant 
155 isolates/samples as false negative. Calculated sensitivities and specificities were applied to the 
156 number of N. gonorrhoeae infections and the prevalence of resistance for 2016 in England and Wales 
157 acquired from Public Health England (PHE) STI and Gonococcal Resistance to Antimicrobial 
158 Surveillance Program (GRASP) data sets [11, 18], to determine positive predictive values (PPV) and 
159 negative predictive values (NPV). Wilson score interval was used to calculate 95% confidence intervals 
160 (CI). 
161 Results 
162 Macrolide resistance 
163 In N. gonorrhoeae, mutations within domain V of the 23S rRNA gene, A to G or C to T substitution at 
164 A2059 and C2611, respectively, are associated with azithromycin resistance (p<0.001). Of the 366 
165 isolates harbouring 23S rRNA mutations with the specific number of mutated alleles reported, five 
166 were non-resistant and each had only one allele mutated. All isolates with two or more mutated 
167 alleles from this review were resistant (n=359) (Table 3). 
168 We found data for 1015 isolates for which the numbers of 23S rRNA mutated alleles were recorded 
169 and for which an azithromycin resistance category (i.e. non-resistant, low-level, moderate-level and 
170 high-level resistant could be allocated) (Figure 1). A strong correlation was found between MIC and 
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171 number of mutated alleles, in isolates where MIC was defined as an integer (for example, not as a 
172 range) and the number of mutated alleles was specifically reported (n=571, rs=0.7846; p=<0.001). 
173 A mutation in L22 was only reported once and mutations in L4 were not significantly associated with 
174 resistance. Methylase (erm) genes, mac efflux pump and ere genes were investigated but were 
175 either not associated with resistance, very rare in resistant isolates, or present with 23S rRNA 
176 mutations or where no other resistance associated region was typed. 
177 Mutations in the MtrCDE transporter were found in both the repressor protein, MtrR, and its 
178 promoter. Mutations were identified at 20 positions within MtrR, but only mutations at H105 and 
179 G45 were associated with resistance (p<0.05). These could not be assessed in multivariate logistic 
180 regression analysis with the 23S rRNA mutations as, in the samples in which both 23S rRNA and 
181 mtrCDE mutations were described, absence of 23S rRNA mutations was only found in non-resistant 
182 samples. Furthermore, mutations at H105 and G45 were only present in 17.9% (145/812) and 35.0% 
183 (52/149) of all resistant isolates screened, respectively. Included publications described a number of 
184 rare alterations to the mtr promoter region including: Neisseria meningitidis like promoter; mosaic 
185 promoter; and a range of insertions, deletions and substitutions. Most frequently reported 
186 alterations were an adenine deletion (DelA), a thymidine insertion, and an adenine to cytosine 
187 substitution within the mtr promoter region but these changes were found in a number of both 
188 resistant and non-resistant isolates and none were determined to be independent markers of 
189 resistance by univariate analysis. 
190 Consequently, this review only indicated the A2059G and C2611T mutations within the 23S rRNA 
191 gene to be independent markers of azithromycin resistance, with higher levels of resistance more 
192 likely with increasing numbers of mutated alleles. However, the independent role of MtrR mutations 
193 impacting on resistance could not be discounted. As a diagnostic marker of azithromycin resistance, 
194 use of the presence of either C2611T or A2059G 23S rRNA mutations (n=1015) within at least one 
195 allele gave a sensitivity and specificity of 66.1% (95% CI 62.1 – 70.0%) and 98.9% (95% CI 97.5% - 
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196 99.5%), respectively; when mutations in two or more alleles were used this gave 65.8% (95% CI 61.7 
197 – 69.6%) and 100% (95% CI 99.2 – 100%), respectively. When presence of either at least one 
198 mutated 23S rRNA allele or the MtrR mutations G45 or H105 were considered, in a smaller sample 
199 set of 207, sensitivity was 78.9% (95% CI 70.8 – 85.2%) and specificity 94.0% (95% CI 86.8 – 97.4%).  
200 The sensitivity and specificity of the combined putative diagnostic was applied to the 36,244 [19] 
201 diagnoses of gonorrhoea made in England and Wales in 2016, using a prevalence of macrolide 
202 resistance (MIC >0.5 mg/L) of 10% [11].This gave a positive predictive value (PPV) of 59.5% (95% CI 
203 58.2 – 60.9%) and a negative predictive value (NPV) of 97.6% (95% CI 97.4 – 97.7%). However, when 
204 applying the lower margin of the 95% CI of sensitivity and specificity estimates, a PPV and NPV of 
205 37.4% (95% CI 36.2% – 38.5%) and 96.4% (95% CI 96.2– 96.6%) were obtained, respectively. 
206 Interestingly, applying the lower margins of accuracy of a single 23S rRNA mutant allele to this same 
207 dataset gave a PPV and NPV of 73.6% (95% CI 72.0 - 75.2%) and 95.9% (95% CI 95.6 – 96.1), 
208 respectively.  
209 Fluoroquinolone resistance 
210 Studies investigating fluoroquinolone resistance sequenced the QRDR for gyrA and parC, encoding 
211 the major subunits of DNA gyrase and DNA topoisomerase IV, respectively [13]. The minor subunits 
212 of these proteins, encoded by gyrB and parE, respectively, were investigated in some cases and 
213 mutations detected. No mutations were found in gyrB, and in parE mutations were only present in 
214 isolates also harbouring gyrA mutations. 
215 N. gonorrhoeae isolates frequently harboured multiple mutations in both genes with a total of 7 and 
216 9 amino acid changes within the QRDR of gyrA and parC, respectively. Of these, mutations at S91 
217 and D95 from gyrA and D86 and S87 from parC were significantly higher in resistant isolates 
218 (p<0.05), with wild-type S88 and E91 always found in non-resistant isolates. Mutations at other 
219 residues were present in less than 1% of the total number of resistant isolates where the QRDR was 
220 typed. Importantly, only one resistant isolate harboured a parC mutation (E91G) without an S91 
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221 and/or D95 mutation in gyrA. Multivariate analyses revealed only S91 and D95 to be significantly 
222 associated with resistance, with 98.5% of resistant isolates harbouring one or both of these 
223 mutations (Table 4). Of those isolates with an S91 and D95 genotype and accompanying phenotypic 
224 susceptibility, 2.5% of resistant and 5.6% of non-resistant isolates harboured a D95 mutation only. 
225 Within this same sample set but using only those isolates where S91 is wild-type, D95 mutations 
226 were found in 64% of resistant isolates as opposed to 5.6% of non-resistant isolates. When used 
227 together, diversion from the wild-type at S91 and/or D95 gave a 98.6% (95% CI 98.0 – 99.0%) 
228 sensitivity and 91.4% (95% CI 88.6 – 93.7%) specificity for resistance detection. 
229 As with macrolide resistance, the MtrCDE efflux pump was investigated for association with 
230 ciprofloxacin resistance in N. gonorrhoeae, although in fewer studies. Of the 10 mutations reported 
231 within MtrR, only the G45D polymorphism was significantly higher in resistant isolates (p<0.001), as 
232 was the DelA mtr promoter mutation (p<0.001). The presence of wild-type at H105 in MtrR was only 
233 found in non-resistant samples and therefore could not go forward into multivariate analysis but of 
234 all resistant isolates typed at H105, only 16.0% (43/269) carried the mutation. Both G45D and DelA 
235 mutations were no longer significantly associated with resistance in multivariate analysis when 
236 tested with gyrA S91. 
237 Discussion
238 The spread of antimicrobial resistance threatens to undermine management of many infectious 
239 diseases. Interventions proposed to address this challenge include a more intelligent use of 
240 antibiotics, partly enabled by novel diagnostic technologies that can predict AMR rapidly [1]. These 
241 promise more accurate treatments and the potential to recycle older antibiotics, thus improving 
242 antibiotic stewardship [20]. In this review we sought to appraise the literature for genotypic 
243 candidates associated with macrolide and fluoroquinolone resistance for N. gonorrhoeae and assess 
244 the potential accuracy of these candidate markers if included in AMR diagnostic platforms. 
245
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246 In N. gonorrhoeae, fluoroquinolones have been largely discontinued for empirical therapy because 
247 of high levels of resistance globally, yet in many regions a large proportion of gonococcal strains 
248 remain phenotypically susceptible to ciprofloxacin [11]. Our analysis confirmed the central role of 
249 two mutations in the gyrA gene, representing amino acid changes at S91 and D95, which were both 
250 independently predictive of ciprofloxacin resistance. The data in this review gave a combined 
251 S91/D95 diagnostic a sensitivity and specificity of 98.6% (95% CI 98.0 – 99.0%) and 91.4% (95% CI 
252 88.6 – 93.7%), respectively, for detection of ciprofloxacin resistance. The GRASP report for 2016, 
253 uses MIC ≥1.0 mg/L as the definition for ciprofloxacin resistance [11]. As the EUCAST defined MIC 
254 >0.06 mg/L was used in this review, the 29% prevalence of resistance from GRASP could not be 
255 applied to the 36,244 gonococcal diagnoses reported in England and Wales in 2016. However, 
256 speculating a resistance prevalence of 50% by our definition is not unreasonable and applying the 
257 lower 95% CI margins of sensitivity and specificity to the dataset gives a PPV and NPV of 89.5% (95% 
258 CI 89.1 - 90.0%) and 97.7% (95% CI 97.5 - 98.0%), respectively. In this virtual scenario, of the 18,122 
259 ciprofloxacin “non-resistant” diagnoses of gonorrhoea, the S91/D95 diagnostic test would 
260 potentially identify 16,047. The test would also report around 370 diagnoses to be genotypically 
261 “non-resistant” when in fact phenotypically resistant and around 2075 genotypically resistant when 
262 in fact phenotypically non-resistant. Although minimising the first of these errors is more important 
263 clinically, the second error represents both missed opportunities to identify patients for whom 
264 ciprofloxacin could be used and diagnostic test wastage. Clearly these predictions are dependent on 
265 the availability of an AMR genotypic result at the point of diagnosis prior to treatment, population 
266 prevalence of resistance as well as the molecular accuracy of marker detection. Evaluating these 
267 diagnostic approaches prospectively for accuracy, cost-effectiveness and impact on resistance 
268 spread will be an important factor in future development. However, the data suggest that an 
269 S91/D95 gyrA diagnostic may well be of value, even in particularly high ciprofloxacin resistance 
270 prevalence settings, but more work on the determinants of resistance is required to improve both 
271 sensitivity and specificity. 
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272
273 Although critical for resistance in E. coli, D95 mutation was reported in borderline ciprofloxacin 
274 resistant N. gonorrhoeae in transformation studies or when induced in vitro, but MIC was 16-fold 
275 greater than the wild-type parental strain [21, 22]. Of those isolates wild-type at S91 and resistant in 
276 this review, 64% carried a mutation at D95, compared to just 5.6% in non-resistant strains, with 
277 inclusion of D95 raising sensitivity of detecting AMR from 96.0% (95% CI 95.1 – 96.8%) to 98.5% 
278 (95% CI 98.0 – 99.0%). Inclusion of D95 reduces specificity from 97.1% (95% CI 95.2 – 98.3%) to 
279 91.4% (95% CI 88.6 – 93.7%), meaning more isolates will be labelled resistant when in fact non-
280 resistant, but as ciprofloxacin is no longer recommended for treatment of N. gonorrhoeae, these 
281 people would not have received this treatment anyway, highlighting this as an added value 
282 approach. 
283
284 In this review, we demonstrated a clear association between 23S rRNA mutations at positions A2059 
285 and C2611 and azithromycin resistance in N. gonorrhoeae, particularly if two or more alleles of the 
286 mutated gene were carried. Although using 23S rRNA markers was associated with sensitivity of only 
287 66.1% (95% CI 62.1 – 70.0%) for detecting azithromycin resistance, this could be explained by the 
288 association of mutated alleles with moderate/high-level resistance, combined with the fact that a 
289 significant proportion of resistant samples were low-level resistant (Figure 1). We also found 
290 azithromycin resistance to be associated with mutations in the MtrR protein at H105 and G45, but 
291 could not test the independence of these associations. 
292
293 Applying the lower margin of the 95% CI interval of sensitivity and specificity estimates for a combined 
294 23S rRNA-G45-H105 test, where any deviation from wild-type is regarded as genotypically resistant, 
295 we obtained a PPV and NPV of 37.4% (95%CI 36.2 – 38.5%) and 96.4% (95%CI 96.2 – 96.6%), 
296 respectively. Interestingly, applying the lower margins of accuracy of a single 23S rRNA mutant allele 
297 to this same dataset gave a PPV and NPV of 73.6% (95% CI 72.0 – 75.2%) and 95.9% (95% CI 95.6% – 
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298 96.1%), respectively. The estimates suggest that for macrolide resistance, some value may be obtained 
299 by using the markers to identify azithromycin susceptible cases genotypically but that this would come 
300 at a significant cost in terms of test wastage as a result of misidentifying susceptible cases as resistant. 
301 Again, further work to better understand the genotypic-phenotypic relationships of macrolide AMR 
302 may improve the accuracy of predictions.
303
304 Overexpression of MtrCDE can increase MIC to macrolides [15] and has been associated with 
305 fluoroquinolone resistance when in combination with gyrA or parC mutations [23, 24]. However, this 
306 review found mutations within MtrCDE and its promoter unreliable as targeted independent markers 
307 of azithromycin and ciprofloxacin resistance due to their prevalence in non-resistant isolates, or 
308 association with more definitive resistance markers such as S91. This demonstrates the complicated 
309 nature of designing AMR detection systems when a number of mechanisms can influence the 
310 resistance phenotype and a limitation of using specific targets for resistance detection. Alternative 
311 methods such as sequencing may be able to screen a number of regions associated with resistance 
312 and use wild-type across the entire region as a marker of susceptibility. Furthermore, variation in MIC 
313 reporting necessitated resistance cut-offs which may mean smaller borderline increases or 
314 intermediate MICs associated with certain resistance mechanisms, are missed.
315
316 Rapid NAAT diagnostics have been integrated into SHC clinical care pathways [25] but in the UK 
317 there remains no licenced diagnostic for dual detection of infection and susceptibility at the PoC, 
318 although these are under investigation, for example the Precise study (www.preciseresearch.co.uk)  
319 and SpeeDx assay (https://plexpcr.com/resistanceplus-gc/). Furthermore, use and trials of 
320 laboratory detection of fluoroquinolone resistance in N. gonorrhoeae are underway [26]. However, 
321 implementation and technology choice for the detection of resistance markers presents a series of 
322 challenges. SNP-based resistance detection may require coverage of multiple alleles, such as the 23S 
323 rRNA region in N. gonorrhoeae [15], or account for the occurrence of synonymous SNPs to avoid 
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324 false calling of resistant isolates. Test efficacy is also highly dependent on active surveillance 
325 programmes, monitoring patterns of resistance and associated genotypes, ideally on a global scale 
326 to capture the influence of regional differences in antibiotic usage.  
327 This review provides a critical appraisal of genetic determinants of resistance to fluoroquinolones 
328 and macrolides in N. gonorrhoeae, however, data reporting varied greatly between publications with 
329 differences in both resistance mechanisms and specific mutations selected to screen for and report 
330 MIC. Included publications are also subject to common limitations including sensitivity and 
331 specificity of tests, particularly for studies investigating new methods for resistance detection, 
332 although the majority of publications used sequencing or established PCR based assays.
333 Molecular detection of antibiotic resistance offers the potential to significantly enhance NAAT 
334 diagnostics. Providing susceptibility profiles at the PoC enables a more prompt and accurate 
335 treatment, an invaluable tool in aiding antibiotic stewardship, a key approach to reduction of AMR. 
336 However, such tests should be employed to enhance testing and be performed in conjunction with 
337 culture and sequencing to monitor susceptibility profiles and circulating and emerging genotypes. 
338
339
340
341
342
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344
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500 Table 1. Number of publications included in literature review and data analysis following screening of results from the literature search. 
Inclusion/Exclusion Criteria Macrolide resistance in 
Neisseria gonorrhoeae
Fluoroquinolone 
resistance in 
Neisseria 
gonorrhoeae
Number of studies following literature search, duplicate deletion 
and reference and citation checking 688 613
Inclusion criteria 
not met Targets  Neisseria gonorrhoeae 52 49
Discusses macrolide or fluoroquinolone resistance 243 137
Reports resistance-associated genotype in relation to antibiotic of 
interest 153 239
Exclusion criteria 
(literature review) Not available in English language 21 24
Review data (bibliography and citation check still performed if 
relevant) 52 22
Conference abstracts where results are listed in a full publication 1 8
Number of studies in literature review 62 133
Exclusion criteria 
(data analysis)
Studies listing mutations at gene level only (unless resistance is 
result of gene presence e.g. erm)a 3 8
Non-clinical samples e.g. laboratory and reference strainsa 10 21
Repeat data sets 7 23
Cannot determine number of isolates for each genotype 0 3
Number of studies in literature review used in data analysis 42 79
501 aThese included strains selected due to known mutation profiles e.g. for testing of new methodology or antibiotics 
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502 Table 2. Criteria used to determine publication suitability for analysis
Data required from each study for inclusion in analysis
Analysis conducted All isolates genotyped
Region/SNPs 
genotyped
Treatment 
outcome 
or MIC
Treatment regimen Treatment dose
Position of mutation and 
any change from wild-
type detected
Genotype 
after 
mutation
Sequence of 
entire region 
available
Associated 
figure or 
table in this 
review
Comments
Proportion of resistant 
isolates with gyrA/parC 
QRDR  mutations in N. 
gonorrhoeae
Yes or a 
random 
selection
QRDR of gyrA or 
parC Yes Ciprofloxacin only No Yes No Yes None
Association between 
ciprofloxacin resistance 
and fluoroquinolone 
resistance determinants in 
N. gonorrhoeae
No See comments Yes Ciprofloxacin only No
Yes 
(MtrR mutations only 
recorded to mutate to 
one residue so these 
were included)
No
Only 
mutations 
being 
investigated
None
Potential resistance 
determinants were 
investigated individually: 
gyrA and parC QRDR 
mutations and Mtr 
promoter and protein 
mutations.
Determining independent 
markers of ciprofloxacin 
resistance in N. 
gonorrhoeae No
S91 and D95 in 
gyrA and D86 
and S87 in parC 
and DelA and 
G45D from the 
Mtr 
Yes Ciprofloxacin only No Yes No No None
Those mutations 
significant in the univariate 
were analysed in the 
multivariate, firstly using 
S91, D95 from gyrA with 
Mtr mutations then S91, 
D95 with parC mutations. 
Sensitivity and specificity 
of ciprofloxacin resistance 
markers for N. 
gonorrhoeae
No S91 and D95 in gyrA Yes Ciprofloxacin only No Yes (S91 and D95) No
S91 and D95 
only Table 4
Association with 
azithromycin resistance for 
macrolide resistance 
determinants in N. 
gonorrhoeae No See comments Yes Azithromycin only No
Yes 
(MtrR mutations only 
recorded to mutate to 
one residue were 
included)
No
Only 
mutations 
being 
investigated
None
Potential resistance 
determinants were 
investigated individually: 
erm genes; 23S rRNA 
mutations; L4 and L22 
mutations and Mtr 
promoter and protein 
mutations
Azithromycin resistance 
and number of mutated 
23S rRNA alleles in N. 
gonorrhoeae
No A2059 and 
C2611
Yes and 
possible to 
categorise 
as low, 
moderate 
or high 
Azithromycin only No Yes and number of 
alleles mutated 
No No Table 4 and 
Figure 1. 
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503 QRDR, quinolone resistance determining region. 
504
505
level 
resistant
Sensitivity and specificity 
of 23S rRNA mutations as 
azithromycin resistance 
markers for N. 
gonorrhoeae
No
A2059 and 
C2611, number 
of 23S rRNA 
alleles mutated
Yes Azithromycin only No Yes No A2059 and C2611 only None
Sensitivity and specificity 
of 23S rRNA, MtrR G45 
and H105 mutations as 
azithromycin resistance 
markers for N. 
gonorrhoeae 
No
A2059 and 
C2611 of 23S 
rRNA, number 
of 23S rRNA 
alleles mutated, 
G45 and H105 of 
MtrR
Yes Azithromycin only No Yes No
A2059 and 
C2611 of 23S 
rRNA, G45 
and H105 of 
MtrR all 
required
None
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506
507
508 Table 3. Number of mutated alleles of the 23S rRNA gene and azithromycin resistance in Neisseria 
509 gonorrhoeae.
510
511
512
513
514
515
516
517
518
519
520
521
522
523
Number of alleles 
harbouring a C2611T 
or A2059G mutation
Number of azithromycin 
resistant isolates- n=546 (%)
Number of azithromycin non-
resistant isolates- n=469 (%)
0 185 464
1 2 5
2 21 0
3 26 0
4 312 0
0 1 2 3 4
0
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MoLR
LoLR
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Number of 23S rRNA alleles with A2059 or C2611 mutations
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r o
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524 Figure 1. Level of azithromycin resistance with number of mutated 23S rRNA alleles in Neisseria 
525 gonorrhoeae. Only isolates that could be categorised in to macrolide resistance levels are included 
526 in the figure (n=1015). Non-Resistant: MIC≤0.5 mg/L; LoLR= low-level resistance: MIC>0.5mg/L and 
527 <2mg/L; MoLR=moderate level resistance: MIC ≥2mg/L and <256mg/L; HiLR=high level resistance: 
528 MIC ≥256mg/L. Spearman rank correlation coefficient (rs) between actual MIC and numbers of 
529 mutated alleles =0.7846; p=0.0000005 (n=571)
530
531
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532 Table 4. Mutations within DNA gyrase at codons S91 and D95 and association with 
533 fluoroquinolone resistance in Neisseria gonorrhoeae. 
gyrA S91 and D95 genotype and ciprofloxacin susceptibility (n=2678)
Genotype Number of resistant isolates (%). 
n=2211 
Number of non-resistant isolates 
(%). n=467 
S91 and D95 mutation 1702 (77.0) 6 (1.3)
S91 mutation only 421 (19.0) 8 (1.7)
D95 mutation only 56 (2.5) 26 (5.6)
Wild-type at both 
residues
32 (1.5) 427 (91.4)
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Search terms for the four searches were constructed and performed in OvidSP. Both Medline and 
EMBASE databases were searched which differ slightly in terms for mapping to subject heading so 
the details for each are listed. 
1. Fluoroquinolone resistance in Neisseria gonorrhoeae 
MEDLINE 
1. exp Neisseria gonorrhoeae/
2. Neisseria gonorrh?eae.ti,ab.
3. 1 or 2
4. exp DNA Gyrase/
5. exp DNA Topoisomerase IV/
6. gyrase.ti,ab.
7. (topoisomerase IV or topoisomerase 4).ti,ab.
8. (parC or parE or gyrA or gyrB).ti,ab.
9. 4 or 5 or 6 or 7 or 8
10. exp Genetics/
11. (gene* or genotyp* or genom*).ti,ab.
12. 10 or 11
13. exp Fluoroquinolones/
14. (fluoroquinolone* or ciprofloxacin).ti,ab.
15. 13 or 14
16. 12 and 15
17. 9 or 16
18. 3 and 17
EMBASE
1. exp Neisseria gonorrhoeae/
2. Neisseria gonorrh?eae.ti,ab.
3. 1 or 2
4. exp DNA topoisomerase IV/
5. exp "DNA topoisomerase (ATP hydrolysing)"/
6. gyrase.ti,ab.
7. (topoisomerase IV or topoisomerase 4).ti,ab.
8. (parC or parE or gyrA or gyrB).ti,ab.
9. 4 or 5 or 6 or 7 or 8
10. exp genetics/
11. (gene* or genotyp* or genom*).ti,ab.
12. 10 or 11
13. exp quinolone derivative/
14. (fluoroquinolone* or ciprofloxacin).ti,ab.
15. 13 or 14
16. 12 and 15
17. 9 or 16
18. 3 and 17
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2. Macrolide resistance in Neisseria gonorrhoeae 
MEDLINE 
1. exp Neisseria gonorrhoeae/
2. neisseria gonnorhoeae.ti,ab.
3. 1 or 2
4. exp RNA, Ribosomal, 23S/
5. (23S or rrna or ribosomal RNA).ti,ab.
6. 4 or 5
7. exp Methyltransferases/
8. (ermB or ermF or methylase or      
methyltransferase).ti, ab.
9. 7 or 8
10. 6 or 9
11. exp Genetics/
12. (gene? or genetic? genotype? or genotypic or 
genome? or genomic?).ti,ab.
13. 7 or 8
14. exp Macrolides/
15. (macrolide? or azithromycin).ab,ti.
16. 10 or 11
17. 9 and 12
18. 6 or 13
19. 3 and 14
EMBASE
1. exp Neisseria gonorrhoeae/
2. neisseria gonnorhoeae.ti,ab.
3. 1 or 2
4. exp RNA 23S/
5. (23S or rrna or ribosomal RNA).ti,ab.
6. 4 or 5
7. exp RNA methyltransferase/
8. (ermB or ermF or methylase or      
methyltransferase).ti, ab.
9. 7 or 8
10. 6 or 9
11. exp genetics/
12. (gene* or genotyp* or genom*)
.ti,ab.
13. 7 or 8
14. exp macrolide/
15. (macrolide* or azithromycin).ab,ti.
16. 10 or 11
17. 9 and 12
18. 6 or 13
19. 3 and 14
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